06 December 2017 | News
The new funding aims to increase the resources available to market and to develop the next generation of robotics dedicated to the treatment of strokes
To treat the vascular diseases Robocath, designs and develops innovative robotic solutions. The company announced an increase in capital of €1.7 million ($2M).
In total capital, €1.25 million ($1.5M) contribution is from Credit Agricole Innovations ET Territoires (CAIT); a fund dedicated to technological innovation in France, managed by Supernova Invest.
Co-owned by Amundi and the CEA, Supernova Invest is a key player in investment capital in Europe; particularly in France.
Cardio Participation, a holding company bringing together several business angels, also invested €450,000 ($530K).
This latest financial contribution supplements the €4.7 million ($5.6M) rose by Robocath in a previous round of fund raising in May.
R-One TM is a unique technology that optimizes and increases the safety of robotic-assisted coronary angioplasty.
This medical procedure consists of revascularizing the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood.
This type of procedure is performed more than one million times each year.
There are many benefits to R-OneTM, for both the patient and the doctor.
The technology allows the surgeon to operate with extreme precision and in optimal conditions.
Intuitive to use, the technology allows the surgeon to operate from a seated position and to use a portable protective screen to guard against X-rays. This first robotic platform will be marketed in Europe and the Middle East in 2018.
Due to this funding, Robocath will also begin researching and developing the next generation of robotic solutions.
The new platform will be used to treat neurovascular diseases such as strokes; the second leading cause of death in the world after heart attacks. The new solution will also aim to improve care for these conditions.